Expertise in
25
conditions

Dr. Sumanta K. Pal

Oncology
City Of Hope Comprehensive Cancer Center-Duarte
1500 Duarte Rd, 
Duarte, CA 
Offers Telehealth
Expertise in
25
conditions
City Of Hope Comprehensive Cancer Center-Duarte
1500 Duarte Rd, 
Duarte, CA 

Overview

Sumanta Pal is an Oncologist practicing medicine in Duarte, California.

Dr. Pal is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

He is actively involved in clinical research, co-authoring 674 peer reviewed articles and participating in 22 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

City Of Hope Comprehensive Cancer Center-Duarte
1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Assessing Feasibility of an App-Based Mindfulness Intervention for Patients With Metastatic Renal Cell Carcinoma
Assessing Feasibility of an App-Based Mindfulness Intervention for Patients With Metastatic Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Other, Device
Study Phase: Not Applicable
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 1
Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma
Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Drug, Biological
Study Drugs: Cabozantinib S-malate, Clostridium Butyricum CBM 588 Probiotic Strain, Nivolumab
Study Phase: Phase 1
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
Enrollment Status: Terminated
Publish Date: March 03, 2026
Intervention Type: Drug
Study Drugs: DFF332, RAD001, PDR001, NIR178
Study Phase: Phase 1
E-Interventions to Treat Fear of Cancer Recurrence for Patients With Localized Renal Cell Carcinoma
E-Interventions to Treat Fear of Cancer Recurrence for Patients With Localized Renal Cell Carcinoma
Enrollment Status: Withdrawn
Publish Date: June 26, 2025
Intervention Type: Other
The Perception of Cure Among Patients With Metastatic Cancer
The Perception of Cure Among Patients With Metastatic Cancer
Enrollment Status: Withdrawn
Publish Date: May 23, 2025
Intervention Type: Other
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
View 9 Less Clinical Trials

670 Total Publications

Regional Variation in Bladder Cancer Clinical Trial Availability in the US.
Regional Variation in Bladder Cancer Clinical Trial Availability in the US.
Journal: JAMA network open
Published: September 03, 2026
Similar Doctors
Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

City Of Hope - Duarte Main Campus

1500 E Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
626-256-4673
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alex Herrera is an Oncologist practicing medicine in Duarte, CA. He has been practicing medicine for over 17 years. Dr. Herrera is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Colonoscopy. Dr. Herrera is board certified in American Board Of Internal Medicine, Hematology and American Board Of Internal Medicine, Oncology.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
626-275-8064
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hope Rugo is an Oncologist practicing medicine in Duarte, California. Dr. Rugo is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Bone Marrow Aspiration, and Vertebroplasty.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Ravi Salgia, M.D., PH.D.

1500 Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ravi Salgia is an Oncologist practicing medicine in Duarte, California. Dr. Salgia is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Gastrostomy.

Frequently Asked Questions about Dr. Sumanta K. Pal

How do I make an appointment with Dr. Sumanta K. Pal?

You can book an appointment with Dr. Sumanta K. Pal by calling their office at 888-304-3959. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sumanta K. Pal a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sumanta K. Pal is classified as an Elite expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sumanta K. Pal specialize in?

While Dr. Sumanta K. Pal is a Oncology, they have specific expertise in Renal Cell Carcinoma (RCC), Urothelial Cancer, and Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Sumanta K. Pal participate in research or clinical trials?

Yes. Dr. Sumanta K. Pal has published 670 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Sumanta K. Pal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sumanta K. Pal accept my insurance?

Dr. Sumanta K. Pal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 888-304-3959 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pal's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 9 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile